Atara Biotherapeutics, Inc. (NASDAQ:ATRA) – Analysts at Jefferies Group upped their FY2019 EPS estimates for shares of Atara Biotherapeutics in a report released on Wednesday. Jefferies Group analyst M. Raycroft now expects that the biotechnology company will earn ($5.23) per share for the year, up from their previous estimate of ($5.37). Jefferies Group currently has a “Buy” rating and a $30.00 target price on the stock. Jefferies Group also issued estimates for Atara Biotherapeutics’ FY2020 earnings at ($4.69) EPS and FY2021 earnings at ($3.49) EPS.

Several other research analysts have also commented on the stock. BidaskClub lowered shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, August 22nd. Zacks Investment Research upgraded shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating and set a $15.00 price objective on the stock in a research note on Tuesday, August 22nd. ValuEngine upgraded shares of Atara Biotherapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. Canaccord Genuity reiterated a “buy” rating and set a $47.00 price objective on shares of Atara Biotherapeutics in a research note on Monday, September 11th. Finally, Goldman Sachs Group reissued a “neutral” rating and set a $20.00 price target on shares of Atara Biotherapeutics in a research report on Friday, October 6th. Three analysts have rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $24.40.

Shares of Atara Biotherapeutics (ATRA) traded up $1.10 during mid-day trading on Friday, hitting $14.80. 341,470 shares of the stock traded hands, compared to its average volume of 228,673. Atara Biotherapeutics has a 1-year low of $11.80 and a 1-year high of $23.00.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($1.02) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.97) by ($0.05).

In related news, EVP Gad Soffer sold 7,000 shares of Atara Biotherapeutics stock in a transaction dated Friday, November 17th. The stock was sold at an average price of $15.00, for a total value of $105,000.00. Following the transaction, the executive vice president now owns 166,342 shares of the company’s stock, valued at approximately $2,495,130. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Christopher Haqq sold 6,000 shares of Atara Biotherapeutics stock in a transaction dated Friday, September 15th. The stock was sold at an average price of $15.30, for a total value of $91,800.00. Following the completion of the transaction, the executive vice president now directly owns 349,305 shares in the company, valued at approximately $5,344,366.50. The disclosure for this sale can be found here. In the last three months, insiders have sold 45,988 shares of company stock valued at $670,920. Corporate insiders own 16.20% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP grew its stake in Atara Biotherapeutics by 2.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 21,718 shares of the biotechnology company’s stock valued at $304,000 after acquiring an additional 610 shares in the last quarter. Teachers Advisors LLC grew its stake in shares of Atara Biotherapeutics by 2.4% in the 2nd quarter. Teachers Advisors LLC now owns 47,156 shares of the biotechnology company’s stock valued at $660,000 after buying an additional 1,110 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of Atara Biotherapeutics by 7.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,377 shares of the biotechnology company’s stock valued at $285,000 after buying an additional 1,369 shares in the last quarter. Alps Advisors Inc. grew its stake in shares of Atara Biotherapeutics by 5.8% in the 2nd quarter. Alps Advisors Inc. now owns 26,274 shares of the biotechnology company’s stock valued at $368,000 after buying an additional 1,445 shares in the last quarter. Finally, Voya Investment Management LLC grew its stake in shares of Atara Biotherapeutics by 16.2% in the 2nd quarter. Voya Investment Management LLC now owns 11,813 shares of the biotechnology company’s stock valued at $165,000 after buying an additional 1,651 shares in the last quarter. 85.61% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Atara Biotherapeutics, Inc. (ATRA) to Post FY2019 Earnings of ($5.23) Per Share, Jefferies Group Forecasts” was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2017/12/08/atara-biotherapeutics-inc-atra-to-post-fy2019-earnings-of-5-23-per-share-jefferies-group-forecasts.html.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Earnings History and Estimates for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.